Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $49

Benzinga Newsdesk www.benzinga.com Positive 52.3%

Neg 0% Neu 0% Pos 52.3%

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $43 to $49.